Sat Kartar Life Limited receives NSE approval for 5,50,000 convertible warrants issue
Sat Kartar Life · Pharmaceuticals & Biotechnology
Key highlights
- Company applied on October 01, 2026 for In-Principle Approval under SEBI Regulation 28(1)
- NSE granted approval via letter Ref: NSE/LIST/57819 dated November 03, 2026
- Warrants to be issued through preferential issue totaling 5,50,000 fully convertible warrants
Why it's rated notable: The filing reports NSE in-principle approval for 5,50,000 fully convertible warrants via preferential issue, with no issue price or proceeds stated and the approval not yet a completed issue, so the level stays at medium without a figure.
Original filing
Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
Read the filing on NSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sat Kartar Life
- Fundraise / allotmentNotableSat Kartar Life Limited held Extra-Ordinary General Meeting on October 23, 2026
Other fundraise / allotment filings this fortnight
- Clean Max Enviro: Q2 results, NCDs up to Rs 3,000 crore approved, IFSC subsidiary planned
- Lloyds Metals and Energy Limited approves Q2 results, investment, and fundraising plans
- Lloyds Metals approves Q2 results, ₹625 crore TEIL investment and USD 300 million debt
- Mena Mani Industries approves Sept 2026 results, hotel venture and software expansion
- CL Educate Limited approves ₹140 Cr fund raise and reports Q2 FY27 financials
- Dev Accelerator Limited announces financial results and NCD issuance plans
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.